Japan's health ministry grants fast-track approval to Shionogi & Co.'s oral COVID-19 drug, making it the country's first domestically-produced oral medicine against the virus.
Paxlovid (Pfizer) and molnupiravir (Merck) are the go-to treatments for non-hospitalized patients, replacing nearly all the monoclonal antibody infusions, which.